Ralliant (NYSE:RAL) Hits New 1-Year High – Here’s Why

Shares of Ralliant Corporation (NYSE:RAL) hit a new 52-week high on Tuesday . The stock traded as high as $64.04 and last traded at $63.96, with a volume of 59398 shares traded. The stock had previously closed at $61.03.

Analyst Ratings Changes

Several brokerages recently weighed in on RAL. Vertical Research downgraded Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a research report on Wednesday, May 27th. Evercore began coverage on Ralliant in a research report on Tuesday. They set an “outperform” rating and a $80.00 price objective for the company. Morgan Stanley upped their price objective on Ralliant from $45.00 to $68.00 and gave the stock an “overweight” rating in a research report on Thursday, May 14th. Zacks Research upgraded Ralliant from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Finally, Barclays upped their price objective on Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $67.30.

Ralliant Trading Up 0.4%

The business has a fifty day simple moving average of $51.16 and a 200-day simple moving average of $49.32. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The firm has a market cap of $6.86 billion and a price-to-earnings ratio of -5.59.

Ralliant (NYSE:RAL) last issued its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The business had revenue of $534.60 million during the quarter. The firm’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities analysts forecast that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, June 8th. Ralliant’s dividend payout ratio is presently -1.83%.

Hedge Funds Weigh In On Ralliant

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Allworth Financial LP increased its holdings in Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares in the last quarter. Rothschild Investment LLC increased its holdings in Ralliant by 98.1% in the 4th quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock worth $31,000 after purchasing an additional 303 shares in the last quarter. Keybank National Association OH increased its holdings in Ralliant by 1.6% in the 4th quarter. Keybank National Association OH now owns 19,667 shares of the company’s stock worth $1,001,000 after purchasing an additional 305 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Ralliant by 49.6% in the fourth quarter. UMB Bank n.a. now owns 983 shares of the company’s stock valued at $50,000 after buying an additional 326 shares during the period. Finally, Maryland State Retirement & Pension System raised its position in shares of Ralliant by 1.5% during the fourth quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock worth $1,117,000 after acquiring an additional 329 shares during the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.